Nexalin Technology, Inc. (NXL) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Nexalin Technology, Inc. is a medical device company developing non-invasive neurostimulation products (Gen-1, Gen-2 "SYNC", and Gen-3 "HALO") to treat mental health conditions such as anxiety, insomnia, depression, and Alzheimer's disease. The company is classified as a Smaller Reporting Company and an Emerging Growth Company. As of November 13, 2025, there were 18,651,939 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $18,149 | $36,031 | $129,752 | $141,542 |
| Gross Profit | $14,201 | $23,337 | $89,408 | $112,445 |
| Operating Expenses | $2,359,832 | $2,531,854 | $6,067,122 | $4,991,695 |
| Net Loss | $(2,276,311) | $(2,448,257) | $(5,845,635) | $(4,773,907) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.23) | $(0.37) | $(0.55) |
| Cash & Equivalents | $590,075 (as of Sept 30, 2025) | |||
| Short-Term Investments | $3,762,602 (as of Sept 30, 2025) | |||
| Total Current Liabilities | $357,524 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(90,490,866) (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 50% in Q3 2025 compared to Q3 2024, driven by lower licensing fees and equipment sales. YTD revenue decreased 8%.
- Expense Fluctuations: While total operating expenses decreased slightly in Q3 2025 ($172k decrease), YTD expenses increased 22% due to higher R&D spending ($405k increase) and stock-based compensation ($283k increase).
- Capital Structure: The company raised approximately $4.65 million in net proceeds from the sale of common stock during the first nine months of 2025. Warrants previously outstanding expired and were delisted in September 2025.
- Investment Activity: Short-term investments increased from $2.9 million to $3.8 million, with net cash used in investing activities decreasing significantly due to active trading of these securities.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. The company has an accumulated deficit of ~$90.5 million and expects to continue incurring losses. Current cash and investments are deemed insufficient to meet anticipated requirements without additional capital.
- Regulatory Progress: In October 2025, the FDA formally accepted a Q-Submission for the Gen-2 "SYNC" system for the treatment of Alzheimer's disease and dementia. A regulatory meeting is scheduled for later in the year. The Gen-3 "HALO" device remains in the pre-submission process.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT controls. Management concluded disclosure controls were not effective as of September 30, 2025.
- Legal & Contingencies: A lawsuit regarding unpaid wages and sexual harassment was settled in May 2025. The company is also in final settlement discussions with the California Employment Development Department (EDD) regarding a tax liability reduced to approximately $30,000.
- Subsequent Events: In October 2025, the company amended its Equity Distribution Agreement (ATM Program) to increase the offering size to $10 million. As of the filing date, approximately $4.27 million remained available for sale.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.35 million in total liquid assets (cash + short-term investments) against the burn rate of ~$3.8 million in operating cash outflows for the nine-month period.
- Capital Raise Execution: Monitor the utilization of the newly expanded $10 million ATM program to determine if the company can secure the necessary funding to avoid insolvency.
- Regulatory Milestones: Track the outcome of the FDA regulatory meeting regarding the Gen-2 SYNC system for Alzheimer's, as this is critical for future revenue potential.
- Internal Control Remediation: Review future filings for progress on remediating the material weaknesses in financial reporting and IT controls.
- Revenue Sustainability: Assess the decline in licensing revenue and the timeline for commercialization of Gen-2 and Gen-3 devices in the U.S. market.